BG106240A - Полиморфна сол - Google Patents

Полиморфна сол

Info

Publication number
BG106240A
BG106240A BG106240A BG10624001A BG106240A BG 106240 A BG106240 A BG 106240A BG 106240 A BG106240 A BG 106240A BG 10624001 A BG10624001 A BG 10624001A BG 106240 A BG106240 A BG 106240A
Authority
BG
Bulgaria
Prior art keywords
polymorphic salt
polymorphic
migraine
agonist
receptors
Prior art date
Application number
BG106240A
Other languages
English (en)
Other versions
BG65161B1 (bg
Inventor
Arthur Bentley
Simon Arnold Howard-Field
Ronald Ogilvie
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG106240A publication Critical patent/BG106240A/bg
Publication of BG65161B1 publication Critical patent/BG65161B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретението се отнася до кристална полиморфна форма (2S,3S)-N-(метокси-5-t- бутилфенилметил-2- дифенилметил-1-азабицикло (2,2,2) октан-3-амин цитрат (цитратен монохидрат) и негов фармацевтичен състав. Фармацевтичният състав на полиморфната форма на цитратния монохидрат е подходящ за лечение на повръщане. Прилагането му се състои в незабавно освобождаване на орално дозирана форма, за предпочитане чрез таблетка или капсула, или интравенозно.
BG106240A 1999-09-28 2001-12-19 Полиморфна сол BG65161B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9922963.5A GB9922963D0 (en) 1999-09-28 1999-09-28 Polymorphic salt

Publications (2)

Publication Number Publication Date
BG106240A true BG106240A (bg) 2002-07-31
BG65161B1 BG65161B1 (bg) 2007-04-30

Family

ID=10861767

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106240A BG65161B1 (bg) 1999-09-28 2001-12-19 Полиморфна сол

Country Status (50)

Country Link
US (1) US6369094B1 (bg)
EP (1) EP1233960B1 (bg)
JP (1) JP3795395B2 (bg)
KR (1) KR100479897B1 (bg)
CN (1) CN1155594C (bg)
AP (1) AP2004A (bg)
AR (1) AR025779A1 (bg)
AT (1) ATE246185T1 (bg)
AU (1) AU779580B2 (bg)
BG (1) BG65161B1 (bg)
BR (1) BR0014272A (bg)
CA (1) CA2379572C (bg)
CO (1) CO5180567A1 (bg)
CR (1) CR6561A (bg)
CU (1) CU23200A3 (bg)
CZ (1) CZ2002971A3 (bg)
DE (1) DE60004262T2 (bg)
DK (1) DK1233960T3 (bg)
DZ (1) DZ3254A1 (bg)
EA (1) EA004510B1 (bg)
EE (1) EE200200171A (bg)
EG (1) EG24143A (bg)
ES (1) ES2200911T3 (bg)
GB (1) GB9922963D0 (bg)
GE (1) GEP20043365B (bg)
GT (1) GT200000159A (bg)
HK (1) HK1048628B (bg)
HR (1) HRP20020270B1 (bg)
HU (1) HUP0202821A3 (bg)
IL (1) IL147154A (bg)
IS (1) IS2162B (bg)
MA (1) MA26821A1 (bg)
MX (1) MXPA02003311A (bg)
MY (1) MY121170A (bg)
NO (1) NO321936B1 (bg)
NZ (1) NZ516093A (bg)
OA (1) OA12024A (bg)
PA (1) PA8498901A1 (bg)
PE (1) PE20010662A1 (bg)
PL (1) PL354960A1 (bg)
PT (1) PT1233960E (bg)
SI (1) SI1233960T1 (bg)
SK (1) SK3982002A3 (bg)
TN (1) TNSN00187A1 (bg)
TR (1) TR200200804T2 (bg)
TW (1) TWI265926B (bg)
UA (1) UA72272C2 (bg)
WO (1) WO2001023377A2 (bg)
YU (1) YU2602A (bg)
ZA (1) ZA200202406B (bg)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008283B2 (en) * 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
US7214711B2 (en) * 1998-12-23 2007-05-08 Neurotherapeutics Pharma Llc Method of treating migraine headache without aura
US20060025387A1 (en) * 1998-12-23 2006-02-02 Cytoscan Sciences Llc Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
CA2588465C (en) * 2004-12-03 2013-10-01 Merck & Co., Inc. Pharmaceutical composition containing an anti-nucleating agent
WO2007047447A2 (en) * 2005-10-17 2007-04-26 Neurotherapeutics Pharma, Inc. Diuretic-like compound analogs useful for regulation of central nervous system disorders
KR100814109B1 (ko) * 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
TWI394753B (zh) 2006-03-17 2013-05-01 Otsuka Pharma Co Ltd 新穎替妥牟拉（ｔｅｔｏｍｉｌａｓｔ）晶體
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
RU2602865C2 (ru) 2009-10-26 2016-11-20 Мерк Шарп И Доум Корп. Твердые фармацевтические композиции, содержащие ингибитор интегразы

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5559246A (en) 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5545644A (en) 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5578612A (en) 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5559129A (en) 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
WO1992006973A1 (en) * 1990-10-15 1992-04-30 Pfizer Inc. Indole derivatives
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
ID24528A (id) * 1997-07-03 2000-07-20 Pfizer Komposisi-komposisi obat farmasi yang mengandung eletriptan hemisulfat dan kafein

Also Published As

Publication number Publication date
ATE246185T1 (de) 2003-08-15
EE200200171A (et) 2003-06-16
BR0014272A (pt) 2002-05-21
HK1048628A1 (en) 2003-04-11
AU6721300A (en) 2001-04-30
IS6223A (is) 2002-01-08
PA8498901A1 (es) 2004-02-07
UA72272C2 (uk) 2005-02-15
TR200200804T2 (tr) 2002-07-22
YU2602A (sh) 2004-11-25
JP2003510318A (ja) 2003-03-18
DE60004262D1 (de) 2003-09-04
GEP20043365B (en) 2004-05-10
CO5180567A1 (es) 2002-07-30
EA004510B1 (ru) 2004-04-29
US6369094B1 (en) 2002-04-09
SK3982002A3 (en) 2003-05-02
GT200000159A (es) 2002-03-20
EP1233960B1 (en) 2003-07-30
ES2200911T3 (es) 2004-03-16
JP3795395B2 (ja) 2006-07-12
HRP20020270A2 (en) 2003-06-30
AR025779A1 (es) 2002-12-11
IL147154A (en) 2005-11-20
AU779580B2 (en) 2005-01-27
CU23200A3 (es) 2007-04-06
WO2001023377A9 (en) 2002-03-28
CA2379572C (en) 2006-11-14
CR6561A (es) 2005-04-04
PT1233960E (pt) 2003-11-28
WO2001023377A2 (en) 2001-04-05
HUP0202821A3 (en) 2003-12-29
TNSN00187A1 (fr) 2005-11-10
SI1233960T1 (en) 2003-12-31
AP2002002457A0 (en) 2002-06-30
HUP0202821A2 (hu) 2003-01-28
MA26821A1 (fr) 2004-12-20
HK1048628B (zh) 2004-10-21
MXPA02003311A (es) 2002-10-04
IS2162B (is) 2006-11-15
CZ2002971A3 (cs) 2003-04-16
BG65161B1 (bg) 2007-04-30
WO2001023377A3 (en) 2002-03-07
DZ3254A1 (fr) 2001-04-05
DK1233960T3 (da) 2003-10-27
CN1364166A (zh) 2002-08-14
GB9922963D0 (en) 1999-12-01
HRP20020270B1 (en) 2004-04-30
TWI265926B (en) 2006-11-11
IL147154A0 (en) 2002-08-14
PL354960A1 (en) 2004-03-22
EA200200302A1 (ru) 2002-10-31
NO321936B1 (no) 2006-07-24
ZA200202406B (en) 2003-05-28
KR20020032627A (ko) 2002-05-03
MY121170A (en) 2005-12-30
NO20021525L (no) 2002-03-26
NZ516093A (en) 2005-01-28
NO20021525D0 (no) 2002-03-26
OA12024A (en) 2006-04-19
CA2379572A1 (en) 2001-04-05
EG24143A (en) 2008-08-06
AP2004A (en) 2009-06-10
EP1233960A2 (en) 2002-08-28
PE20010662A1 (es) 2001-06-23
KR100479897B1 (ko) 2005-03-31
DE60004262T2 (de) 2004-01-22
CN1155594C (zh) 2004-06-30

Similar Documents

Publication Publication Date Title
BG106240A (bg) Полиморфна сол
JO3360B1 (ar) الشكل البلوري الجديد 3 للأغوميلاتين وعملية تحضيره والمكونات الصيدلانية التي تحتويه
GEP20043362B (en) Novel $G(Y)Crystalline Form of Perindopril Tert- Butylamine Salt, Preparation Method, and Pharmaceutical Compositions Containing Same
GEP20043361B (en)  Crystalline Form of Perindopril Tert-Butylamine Salt,
IL167168A (en) Indoline compound in crystalline form for use in oral solid medicament and such oral solid medicament for treating dysuria
AP1407A (en) Novel ß Crystalline Form of Perindopril Tert-Butylamine Salt, Preparation Method, And Pharmaceutical Compositions Containing Same.
JO2793B1 (en) The new crystalline form 5 of agomelatine, its preparation process and the pharmaceutical ingredients it contains
EE04915B3 (et) Kinuklidiinderivaadid, nende valmistamismeetod, vaheühendid, farmatseutiline kompositsioon ja nende kasutamine
RU94036749A (ru) Замещенные 1-нафтилпиразол-3-карбоксамиды, способ их получения, содержащие их фармацевтические композиции и промежуточные соединения синтеза
UA83870C2 (ru) Замещенные бицикло[3.1.1]гептаном производные бензимидазолона и хиназолинона как агонисты человеческих рецепторов orl1
TW200509906A (en) Crystalline 1-methylcarbapenem compounds
ZA926374B (en) Pharmaceutical agents.
ECSP003681A (es) Sal polimorfica
MA28191A1 (fr) Nouvelle forme cristalline "alpha" du sel de tert -butylamine du perindoprill, son procede de preparation et les compositions pharmaceutiques qui la contiennent.